Component: (Network and Table)
Network
00500 - Statement - Consolidated Statements of Cash Flows
(http://www.amicustherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001178879 (http://www.sec.gov/CIK)
Consolidated Statements of Cash FlowsPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Consolidated Statements of Cash Flows
 
 
 
Operating activities
 
 
 
Net loss
(200,042,000) 
(132,118,000) 
(68,926,000) 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Non-cash interest expense
2,689,000  
492,000  
277,000  
Depreciation
3,242,000  
1,833,000  
1,547,000  
Stock-based compensation
17,504,000  
9,972,000  
6,008,000  
Restructuring charges
69,000  
15,000  
(63,000) 
Change in fair value of warrant liability
265,000  
  
Non-cash changes in the fair value of contingent consideration payable
6,760,000  
4,377,000  
100,000  
Charges to research expense for stock issued in asset acquisition
4,607,000  
  
Loss on extinguishment of debt
13,302,000  
952,000  
 
Foreign currency remeasurement loss
3,660,000  
  
Non-cash income tax benefit
(1,293,000) 
  
Non-cash deferred taxes
(2,449,000) 
  
Loss on disposal of assets
17,000  
  
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(1,419,000) 
  
Inventories
(3,651,000) 
  
Receivable due from collaboration agreements
  
1,083,000  
Prepaid expenses and other current assets
(394,000) 
308,000  
2,293,000  
Other non-current assets
(1,357,000) 
(666,000) 
26,000  
Accounts payable and accrued expenses
7,131,000  
15,467,000  
6,169,000  
Non-current liabilities
825,000  
93,000  
(126,000) 
Deferred reimbursements
 
(864,000) 
(57,000) 
Net cash used in operating activities
(150,534,000) 
 
(100,139,000) 
 
(51,669,000) 
 
Investing activities
 
 
 
Sale and redemption of marketable securities
221,374,000  
290,129,000  
55,914,000  
Purchases of marketable securities
(219,932,000) 
(289,595,000) 
(162,752,000) 
Acquisitions, net of cash acquired
 
(141,060,000) 
 
Purchases of property and equipment
(5,951,000) 
(4,817,000) 
(238,000) 
Net cash used in investing activities
(4,509,000) 
 
(145,343,000) 
 
(107,076,000) 
 
Financing activities
 
 
 
Proceeds from issuance of common stock and warrants, net of issuance costs
97,068,000  
243,042,000  
135,805,000  
Payments of secured loan agreement
(80,000,000) 
(15,291,000) 
(299,000) 
Payment of capital leases
(193,000) 
  
Purchase of vested restricted stock units
(1,282,000) 
(2,044,000) 
 
Proceeds from exercise of stock options
3,036,000  
11,186,000  
3,673,000  
Proceeds from exercise of warrants
 
4,000,000  
 
Payment of contingent consideration
(5,000,000) 
  
Proceeds from issuance of convertible senior notes, net of issuance costs
242,536,000  
  
Premiums paid for Capped Call Confirmations
(13,450,000) 
  
Proceeds from secured loan agreement
30,000,000  
50,000,000  
 
Net cash provided by financing activities
272,715,000  
 
290,893,000  
 
139,179,000  
 
Effect of exchange rate changes on cash and cash equivalents
(131,000) 
  
Net increase/(decrease) in cash and cash equivalents
117,541,000  
 
45,411,000  
 
(19,566,000) 
 
Cash and cash equivalents at beginning of year/ period
69,485,000  
24,074,000  
43,640,000  
Cash and cash equivalents at end of year/period
187,026,000  
 
69,485,000  
 
24,074,000  
 
Supplemental disclosures of cash flow information
 
 
 
Cash paid during the period for interest
2,990,000  
605,000  
1,186,000  
Contingent consideration paid in shares
6,115,000  
  
Capital expenditures funded by capital lease borrowings
944,000